GLP-1 analogues for type 2 diabetes
There is a worldwide shortage of injectable and oral GLP-1 analogue receptor agonist (GLP-1s) medicines for type 2 diabetes. These include Dulaglutide (Trulicity®), Exenatide (Byetta® or Bydureon®), Semaglutide (Ozempic® or Rybelsus®), Liraglutide (Victoza®) and Lixisenatide (Lyxumia®). Due to increased global use, manufacturers are currently unable to produce enough of these diabetic injectable medicines to meet … Continued